RHODOS Trial Results and Insights | Idebenone.org The RHODOS trial investigated whether idebenone could improve or stabilize vision in individuals with Leber’s hereditary optic neuropathy (LHON). Participants received idebenone 900 mg daily or placebo for 24 weeks, with visual acuity measured using standardized ETDRS charts. While the overall difference in vision improvement between groups was not statistically significant, a higher proportion of idebenone-treated patients achieved clinically relevant recovery compared with placebo. Read more: https://www.perrysplacepromotions.org/blog/idebenone-therapy-for-lhon-a-detailed-research-review